CD8-independent tumor cell recognition is a property of the T cell receptor and not the T cell

Journal of Immunology

Volumn 170, Issue 5, 2003, Pages 2582-2589

  Roszkowski, Jeffrey J ^a   Yu, David C ^a   Rubinstein, Mark P ^b   McKee, Mark D ^a   Cole, David J ^b   Nishimura, Michael I ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HLA A2 ANTIGEN; INTERLEUKIN 2; T LYMPHOCYTE RECEPTOR;

ANIMAL CELL; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; CELL SECRETION; CONTROLLED STUDY; CORRELATION ANALYSIS; EFFECTOR CELL; GENE INSERTION; GENETIC TRANSDUCTION; IMMUNOFLUORESCENCE; LYMPHOCYTE FUNCTION; MOLECULAR RECOGNITION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; T LYMPHOCYTE; TUMOR CELL CULTURE;

EID: 0037371116     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.170.5.2582     Document Type: Article

References (46)

1. Kaye, J., G. Kersh, I. Engel, and S. M. Hedrick. 1991. Structure and specificity of the T cell antigen receptor. Semin. Immunol. 3:269.
2. Swain, S. L. 1983. T cell subsets and the recognition of MHC class. Immunol. Rev. 74:129.
3. Swain. S. L., D. P. Dialynas, F. W. Fitch, and M. English. 1984. Monoclonal antibody to L3T4 blocks the function of T cells specific for class 2 major histocompatibility complex antigens. J. Immunol. 132:1118.
4. Strominger, J. L., and D. C. Wiley. 1995. The 1995 Albert Lasker Medical Research Award: the class I and class II proteins of the human major histocompatibility complex. JAMA 274:1074.
5. Eisen, H. N., Y. Sykulev, and T. J. Tsomides. 1996. Antigen-specific T-cell receptors and their reactions with complexes formed by peptides with major histocompatibility complex proteins. Adv. Protein Chem. 49:1.
6. Foote, J., and H. N. Eisen. 2000. Breaking the affinity ceiling for antibodies and T cell receptors. Proc. Natl. Acad. Sci. USA 97:10679.
7. Corr, M., A. E. Slanetz, L. F. Boyd, M. T. Jelonek, S. Khilko, B. K. al Ramadi, Y. S. Kim, S. E. Maher, A. L. Bothwell, and D. H. Margulies. 1994. T cell receptor-MHC class I peptide interactions: affinity, kinetics, and specificity. Science 265:946.
8. Garcia, K. C., C. A. Scott, A. Brunmark, F. R. Carbone, P. A. Peterson, I. A. Wilson, and L. Teyton. 1996. CD8 enhances formation of stable T-cell receptor/MHC class I molecule complexes. Nature 384:577.
9. Doyle, C., and J. L. Strominger. 1987. Interaction between CD4 and class II MHC molecules mediates cell adhesion. Nature 330:256.
10. Ick. Cell 55:301.
11. + tumor infiltrating lymphocyte. Cancer Res. 59:6230.
12. Rosenberg, S. A., B. S. Packard, P. M. Aebersold, D. Solomon. S. L. Topalian, S. T. Toy, P. Simon, M. T. Lotze, J. C. Yang, and C. A. Seipp. 1988. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma: a preliminary report. N. Engl. J. Med. 319:1676.
13. Topalian, S. L., L. M. Muul, D. Solomon, and S. A. Rosenberg. 1987. Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials. J. Immunol. Methods 102:127.
14. McIntosh, J. K., J. J. Mule, M. J. Merino, and S. A. Rosenberg. 1988. Synergistic antitumor effects of immunotherapy with recombinant interleukin-2 and recombinant tumor necrosis factor-α. Cancer Res. 48:4011.
15. Nishimura, M. I., Y. Kawakami, P. Charmley, B. O'Neil, J. Shilyansky, J. R. Yannelli, S. A. Rosenberg, and L. Hood. 1994. T-cell receptor repertoire in tumor-infiltrating lymphocytes. Analysis of melanoma-specific long-term lines. J. Immunother. Emphasis Tumor Immunol. 16:85.
16. McKee, M. D., T. M. Clay, S. A. Rosenberg, and M. I. Nishimura. 1999. Quantitation of T-cell receptor frequencies by competitive PCR: generation and evaluation of novel TCR subfamily and clone specific competitors. J. Immunother. 22:93.
17. Miyoshi, H., U. Blomer, M. Takahashi, F. H. Gage, and I. M. Verma. 1998. Development of a self-inactivating lentivirus vector, J. Virol. 72:8150.
18. Schwartzentruber, D. J., S. L. Topalian, M. Mancini, and S. A. Rosenberg. 1991. Specific release of granulocyte-macrophage colony stimulating factor, tumor necrosis factor-α, and IFN-γ by human tumor-infiltrating lymphocytes after autologous tumor stimulation. J. Immunol. 146:3674.
19. Kawakami, Y., S. Eliyahu, C. Jennings, K. Sakaguchi, X. Kang, S. Southwood, P. F. Robbins, A. Sette, E. Appella, and S. A. Rosenberg. 1995. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J. Immunol. 154:3961.
20. Kawakami, Y., S. Eliyahu, K. Sakaguchi, P. F. Robbins, L. Rivoltini, J. R. Yannelli, E. Appella, and S. A. Rosenberg. 1994. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J. Exp. Med. 180:347.
21. Skipper, J. C., R. C. Hendrickson, P. H. Gulden, V. Brichard, A. Van Pel, Y. Chen, J. Shabanowitz, T. Wolfel, C. L. Slingluff, Jr., T. Boon, et al. 1996. An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins. J. Exp. Med. 183:527.
22. Clay, T. M., M. C. Custer, P. J. Spiess, and M. I. Nishimura. 1999. Potential use of T cell receptor genes to modify hematopoietic stem cells for the gene therapy of cancer. Pathol. Oncol. Res. 5:3.
23. Blank, U., B. Boitel, D. Mege, M. Ermonval, and O. Acuto. 1993. Analysis of tetanus toxin peptide/DR recognition by human T cell receptors reconstituted into a murine T cell hybridoma. Eur. J. Immunol. 23:3057.
24. Hastings, A. E., C. K. Hurley, E. D. Robinson, K. Salerno, E. Hernandez, and J. R. Richert. 1996. Molecular interactions between transfected human TCR, immunodominant myelin basic protein peptide 152-165, and HLA-DR 13. J. Immunol. 157:3460.
25. Alexander-Miller, M. A., G. R. Leggatt, and J. A. Berzofsky. 1996. Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc. Natl. Acad. Sci. USA 93:4102.
26. Zeh, H. J., III. D. Perry-Lalley, M. E. Dudley, S. A. Rosenberg, and J. C. Yang. 1999. High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J. Immunol. 162:989.
27. Sykulev, Y., A. Brunmark, M. Jackson, R. J. Cohen, P. A. Peterson, and H. N. Eisen. 1994. Kinetics and affinity of reactions between an antigen-specific T cell receptor and peptide-MHC complexes. Immunity. 1:15.
28. k complexes: correlation of the dissociation rate with T-cell responsiveness. Proc. Natl. Acad. Sci. USA 91:12862.
29. Kersh, G. J., E. N, Kersh, D. H. Fremont, and P. M. Allen. 1998. High- and low-potency ligands with similar affinities for the TCR: the importance of kinetics in TCR signalling. Immunity 9:817.
30. Lyons, D. S., S. A. Lieberman, J. Hampl, J. J. Boniface, Y. Chien, L. J. Berg, and M. M. Davis. 1996. A TCR binds to antagonist ligands with lower affinities and faster dissociation rates than to agonists. Immunity 5:53.
31. - T cell transfectants that express a high affinity T cell receptor exhibit enhanced peptide-dependent activation. J. Exp. Med. 194:1043.
32. Combadiere, B., C. Sousa, C. Trageser, L. X. Zheng, C. R. Kim, and M. J. Lenardo. 1998. Differential TCR signaling regulates apoptosis and immunopathology during antigen responses in vivo. Immunity 9:305.
33. Lenardo, M. J., S. Boehme, L. Chen, B. Combadiere, G. Fisher, M. Freedman, H. McFarland, C. Pelfrey, and L. Zheng. 1995. Autocrine feedback death and the regulation of mature T lymphocyte antigen responses. Int. Rev. Immunol. 13:115.
34. Dudley, M. E., J. Wunderlich, M. I. Nishimura, D. C. Yu, J. C. Yang, S. L. Topalian, D. J. J. Schwartzentruber, P. Hwu, F. M. Marincola, R. Sherry, et al. 2001. Adoptive transfer of cloned, melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J. Immunother. 24:363.
35. Clay, T. M., M. C. Custer, J. Sachs, P. Hwu, S. A. Rosenberg, and M. I. Nishimura. 1999. Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. J. Immunol. 163:507.
36. Cooper, L. J., M. Kalos, D. A. Lewinsohn, S. R. Riddell, and P. D. Greenberg. 2000. Transfer of specificity for human immunodeficiency virus type 1 into primary human T lymphocytes by introduction of T-cell receptor genes. J. Virol. 74:8207.
37. Orentas, R. J., S. J. Roskopf, G. P. Nolan. and M. I. Nishimura. 2001. Retroviral transduction of a T cell receptor specific for an Epstein-Barr virus-encoded peptide. Clin. Immunol. 98:220.
38. Fujio, K., Y. Misaki, K. Setoguchi, S. Morita, K. Kawahata, I. Kato, T. Nosaka, K. Yamamoto, and T. Kitamura. 2000. Functional reconstitution of class II MHC-restricted T cell immunity mediated by retroviral transfer of the alpha beta TCR complex. J. Immunol. 165:528.
39. Kessels, H. W., M. C. Wolkers, M. D. van den Boom, M. A. van Den Valk, and T. N. Schumacher. 2001. Immunotherapy through TCR gene transfer. Nat. Immunol. 2:957.
40. Stanislawski, T., R. H. Voss, C. Lotz, E. Sadovnikova, R. A. Willemsen, J. Kuball, T. Ruppert, R. L. Bolhuis, C. J. Melief, C. Huber, et al. 2001. Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. Nat. Immunol. 2:962.
41. Willemsen, R. A., M. E. Weijtens, C. Ronteltap, Z. Eshhar, J. W. Gratama, P. Chames, and R. L. Bolhuis. 2000. Grafting primary human T lymphocytes with cancer-specific chimeric single chain and two chain TCR. Gene Ther. 7:1369.
42. Rosenberg, S. A. 1999. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity. 10:281.
43. Boon, T., P. G. Coulie, and B. Van den Eynde. 1997. Tumor antigens recognized by T cells. Immunol. Today 18:267.
44. Alam, S. M., P. J. Travers, J. L. Wung, W. Nasholds, S. Redpath, S. C. Jameson, and N. R. Gascoigne. 1996. T-cell-receptor affinity and thymocyte positive selection. Nature 381:616.
45. Sprent J., D. Lo, E. K. Gao, and Y. Ron. 1988. T cell selection in the thymus. Immunol. Rev. 101:173.
46. Colella, T. A., T. N. Bullock, L. B. Russell, D. W. Mullins, W. W. Overwijk, C. J. Luckey, R. A. Pierce, N. P. Restifo, and V. H. Engelhard. 2000. Self-tolerance to the murine homologue of a tyrosinase:derived melanoma antigen: implications for tumor immunotherapy. J. Exp. Med. 191:1221.